OncoMatch/Clinical Trials/NCT07086456
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
Is NCT07086456 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Surufatinib and Tislelizumab for surufatinib.
Treatment: Surufatinib · Tislelizumab · Concurrent Chemotherapy — This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of surufatinib and tislelizumab in combination with concurrent chemoradiotherapy, followed by consolidation therapy with tislelizumab plus surufatinib, in patients with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR driver gene mutation
Presence of EGFR or ALK driver gene mutations [excluded]
Required: ALK driver gene mutation
Presence of EGFR or ALK driver gene mutations [excluded]
Disease stage
Required: Stage IIIA, IIIB, IIIC
Performance status
WHO 0–1
Demographics
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 9.0 g/dL
Kidney function
Serum creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)
Liver function
Total serum bilirubin ≤ 1.5 × upper limit of normal (ULN); AST and ALT ≤ 2.5 × ULN
Adequate organ and bone marrow function as defined by the following criteria: Forced expiratory volume in 1 second (FEV1) ≥ 800 mL; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 9.0 g/dL; Serum creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula); Total serum bilirubin ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN. Average QTc ≥ 470 ms excluded.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07086456 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require EGFR?
Yes, EGFR driver gene mutation is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK driver gene mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIA or IIIB or IIIC is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify